[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605739":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":11,"locations":17,"responsibleParty":31,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",null,[9],{"type":6,"name":10,"description":10,"armGroupLabels":7,"otherNames":7},"observational diagnostic model development",[12],{"name":13,"role":14,"phone":15,"phoneExt":7,"email":16},"Zheng Zhang","CONTACT","139 0137 1490","doczhz@aliyun.com",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":7,"country":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Department of Urology, Peking University First Hospital, Beijing, 100034","RECRUITING","Beijing","China",{"type":24,"coordinates":25},"Point",[26,27],116.39723,39.9075,{"lat":27,"lon":26},[30],{"name":13,"role":14,"phone":7,"phoneExt":7,"email":16},{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100605739",false,"NCT07166432","Development, Application, and Mechanistic Investigation of a Novel Minimally-Invasive Bidirectional Epidural Cerebellar Stimulation Technique for Cerebellar Cognitive Affective Syndrome","Inclusion Criteria:\n\n* 1\\. Clinically and biochemically confirmed ACTH-dependent or ACTH-independent Cushing syndrome (loss of serum cortisol circadian rhythm, elevated 24-hour urinary free cortisol, and failure to suppress on low-dose dexamethasone suppression test).\n\n  2\\. Cranial MRI demonstrating unequivocal cerebellar atrophy (CCAS imaging criterion: cerebellar hemisphere or vermian volume ≥1.5 SD below age-matched normative data).\n\n  3\\. Established clinical diagnosis of CCAS (meets Schmahmann criteria, CCAS-S total score ≥20).\n\n  4\\. Cerebellar ataxia rating scale (SARATA) ≥10, indicating at least moderate motor ataxia.\n\n  5\\. Positive cognitive impairment screen (MoCA \\\u003C26, or Z-scores ≤-1.5 in at least two cognitive domains).\n\n  6\\. Willingness to undergo minimally invasive epidural cerebellar stimulation and provision of written informed consent.\n\nExclusion Criteria:\n\nPatients with significant systemic disease; occurrence of major complications or irreproducible, critical deviations in data collection or experimental procedures; or any circumstance rendering continued participation inappropriate-including clinical deterioration, serious adverse events, or poor compliance-will result in discontinuation of the subject's enrollment.","ALL","18 Years","85 Years",{"count":42,"type":43},200,"ESTIMATED","OBSERVATIONAL","Building on previous findings regarding microglial immune function and the immunosuppressive effects of glucocorticoids, this project centers on the cerebellum's role in cognitive science. Using Cushing's syndrome-induced cerebellar atrophy leading to CCAS as a model, we aim to elucidate the pathogenic mechanisms governed by the neuro-adrenal-immune network and to uncover the molecular basis by which a novel minimally invasive brain-machine fusion system ameliorates cerebellar ataxia and cognitive impairment.",[47,48,49],"Cerebellar Atrophy","Etiology","Physiopathology","2025-09-03",{"date":52,"type":53},"2025-09-10","ACTUAL",{"date":55,"type":53},"2025-06-28",{"date":57,"type":43},"2028-06-01",{"name":5,"class":6},1]